title: [Effects of ischemia/reperfusion on the phosphotyrosine proteins contents in hippocampus].
abstract: OBJECTIVE
  The effects of three drugs including ketamine(KT), a noncompetitive antagonist of NMDA receptor (NR), nifedipine(ND), a voltage gated calcium channel (VGCC) antagonist and 6, 7dinitroquinoxaline -2, 3-dione(DNQX), a non-NMDA receptor antagonist on the contents of phospho-tyrosine proteins (p-tyr-pr) in the synaptosomal(P2), the crude membrane (P3), and the cytosolic (S3) fractions of hippocampus in forebrain ischemia of mongolian gerbils were studied.
  
  
  RESULTS
  (1) the contents of p-tyr-pr in all three fractions (P2, P3, S3) decreased 15 min after ischemia, but the contents of p-tyr-pr in S3 fraction decreased more obviously than the others did, With the increase of reperfusion time, the contents of p-tyr-pr in all of these fractions recovered gradually, but the p-tyr-pr in S3 fraction increased more rapidly among them, in the P2 fraction, the contents of p-tyr-pr increased slowly, but significantly and sustained longer during reperfusion when compared with that of P3 did. (2) The increase in p-tyr-pr contents induced by cerebral ischemia/reperfusion was partially antagonisted by KT and ND administration prior to cerebral ischemia, under these conditions, DNQX has no effect on it.
  
  
  CONCLUSIONS
  the increase of p-tyr-Pr contents induced by cerebral ischemia/reperfusion is related to NR channel and L-type VGCC, but not to non-NR channel.
authors.affiliation: Research Center of Biochemistry and Molecular Biology, Xu Zhou Medical College, Xuchou 2210020.
authors.forename: L
authors.initials: L
authors.lastname: Pei
authors.forename: Y
authors.initials: Y
authors.lastname: Li
authors.forename: G Y
authors.initials: GY
authors.lastname: Zhang
authors.forename: Z H
authors.initials: ZH
authors.lastname: Gui
authors.forename: Z M
authors.initials: ZM
authors.lastname: Zhu
mesh_terms: D000818:Animals; D002545:Brain Ischemia / Q000378:metabolism*; D002121:Calcium Channel Blockers / Q000494:pharmacology; D015220:Calcium Channels / Q000378:metabolism; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D005849:Gerbillinae; D006624:Hippocampus / Q000378:metabolism*; D007649:Ketamine / Q000494:pharmacology; D009543:Nifedipine / Q000494:pharmacology; D010766:Phosphorylation; D019000:Phosphotyrosine / Q000378:metabolism*; D011810:Quinoxalines / Q000494:pharmacology; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors / Q000378:metabolism; D015427:Reperfusion Injury / Q000378:metabolism*
chemical_list: D002121:Calcium Channel Blockers; D015220:Calcium Channels; D018691:Excitatory Amino Acid Antagonists; D011810:Quinoxalines; D016194:Receptors, N-Methyl-D-Aspartate; D019000:Phosphotyrosine; C056723:FG 9041; D007649:Ketamine; D009543:Nifedipine